Cargando…
Ultrasound‐controlled drug release and drug activation for cancer therapy
Traditional chemotherapy suffers from severe toxicity and side effects that limit its maximum application in cancer therapy. To overcome this challenge, an ideal treatment strategy would be to selectively control the release or regulate the activity of drugs to minimize the undesirable toxicity. Rec...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10190934/ https://www.ncbi.nlm.nih.gov/pubmed/37323693 http://dx.doi.org/10.1002/EXP.20210023 |
_version_ | 1785043375771090944 |
---|---|
author | Tu, Li Liao, Zhihuan Luo, Zheng Wu, Yun‐Long Herrmann, Andreas Huo, Shuaidong |
author_facet | Tu, Li Liao, Zhihuan Luo, Zheng Wu, Yun‐Long Herrmann, Andreas Huo, Shuaidong |
author_sort | Tu, Li |
collection | PubMed |
description | Traditional chemotherapy suffers from severe toxicity and side effects that limit its maximum application in cancer therapy. To overcome this challenge, an ideal treatment strategy would be to selectively control the release or regulate the activity of drugs to minimize the undesirable toxicity. Recently, ultrasound (US)‐responsive drug delivery systems (DDSs) have attracted significant attention due to the non‐invasiveness, high tissue penetration depth, and spatiotemporal controllability of US. Moreover, the US‐induced mechanical force has been proven to be a robust method to site‐selectively rearrange or cleave bonds in mechanochemistry. This review describes the US‐activated DDSs from the fundamental basics and aims to present a comprehensive summary of the current understanding of US‐responsive DDSs for controlled drug release and drug activation. First, we summarize the typical mechanisms for US‐responsive drug release and drug activation. Second, the main factors affecting the ultrasonic responsiveness of drug carriers are outlined. Furthermore, representative examples of US‐controlled drug release and drug activation are discussed, emphasizing their novelty and design principles. Finally, the challenges and an outlook on this promising therapeutic strategy are discussed. |
format | Online Article Text |
id | pubmed-10190934 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101909342023-06-14 Ultrasound‐controlled drug release and drug activation for cancer therapy Tu, Li Liao, Zhihuan Luo, Zheng Wu, Yun‐Long Herrmann, Andreas Huo, Shuaidong Exploration (Beijing) Review Articles Traditional chemotherapy suffers from severe toxicity and side effects that limit its maximum application in cancer therapy. To overcome this challenge, an ideal treatment strategy would be to selectively control the release or regulate the activity of drugs to minimize the undesirable toxicity. Recently, ultrasound (US)‐responsive drug delivery systems (DDSs) have attracted significant attention due to the non‐invasiveness, high tissue penetration depth, and spatiotemporal controllability of US. Moreover, the US‐induced mechanical force has been proven to be a robust method to site‐selectively rearrange or cleave bonds in mechanochemistry. This review describes the US‐activated DDSs from the fundamental basics and aims to present a comprehensive summary of the current understanding of US‐responsive DDSs for controlled drug release and drug activation. First, we summarize the typical mechanisms for US‐responsive drug release and drug activation. Second, the main factors affecting the ultrasonic responsiveness of drug carriers are outlined. Furthermore, representative examples of US‐controlled drug release and drug activation are discussed, emphasizing their novelty and design principles. Finally, the challenges and an outlook on this promising therapeutic strategy are discussed. John Wiley and Sons Inc. 2021-12-28 /pmc/articles/PMC10190934/ /pubmed/37323693 http://dx.doi.org/10.1002/EXP.20210023 Text en © 2021 The Authors. Exploration published by Henan University and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Articles Tu, Li Liao, Zhihuan Luo, Zheng Wu, Yun‐Long Herrmann, Andreas Huo, Shuaidong Ultrasound‐controlled drug release and drug activation for cancer therapy |
title | Ultrasound‐controlled drug release and drug activation for cancer therapy |
title_full | Ultrasound‐controlled drug release and drug activation for cancer therapy |
title_fullStr | Ultrasound‐controlled drug release and drug activation for cancer therapy |
title_full_unstemmed | Ultrasound‐controlled drug release and drug activation for cancer therapy |
title_short | Ultrasound‐controlled drug release and drug activation for cancer therapy |
title_sort | ultrasound‐controlled drug release and drug activation for cancer therapy |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10190934/ https://www.ncbi.nlm.nih.gov/pubmed/37323693 http://dx.doi.org/10.1002/EXP.20210023 |
work_keys_str_mv | AT tuli ultrasoundcontrolleddrugreleaseanddrugactivationforcancertherapy AT liaozhihuan ultrasoundcontrolleddrugreleaseanddrugactivationforcancertherapy AT luozheng ultrasoundcontrolleddrugreleaseanddrugactivationforcancertherapy AT wuyunlong ultrasoundcontrolleddrugreleaseanddrugactivationforcancertherapy AT herrmannandreas ultrasoundcontrolleddrugreleaseanddrugactivationforcancertherapy AT huoshuaidong ultrasoundcontrolleddrugreleaseanddrugactivationforcancertherapy |